PHP18 The Effect of Law for Economical Use of Medications 2006 on the Catchment Population of Community Pharmacies Between 2007-2010  by Boncz, I. et al.
use in the community (spillover effect). CONCLUSIONS: Evergreening drugs suc-
cessfully compete with generics, offsetting cost containment strategies including
generic medication substitution or a hospital RDF, particularly so if hospitals in-
clude evergreening or brand drugs on their RDF. For effectiveness, prescriptions
should be coordinated at the state level rather than from a payer perspective, or
hospitals should implement strategies to systematically switch patients to generic
drugs at discharge.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the number of pharmacies.METHODS:Data were derived from the pharmaceu-
tical database of the Hungarian Health Insurance Fund Administration (OEP), the
only health care financing agency in Hungary. We analysed the 5 years period
between 2006-2010. The number of pharmacies were analysed according to the
number of population of different settlements. RESULTS: The number of commu-
nity pharmacies increased from 2030 (2006) to 2576 (2010) by 546 pieces (26.9 %).
The number of pharmacies showed a different pattern according to the size of
population of settlements. In villages with a population of 0-449, 500-999 and 1000-
1999, the number of pharmacies decreased (3 pieces / 3.6 %; 18 pieces / 20.0 %; 23
pieces / 10.6 % respectively). In cities with a population between 2000-4999 we
found a slight increase in the number of pharmacies (11 pieces / 3.0 %). In bigger
towns there was a clear increase in the number of pharmacies: 5000-9999 popula-
tion 53 pieces / 29.0 %; 10000-49999 194 pieces / 37.1 %; 50000-99999 population 129
pieces / 33.0 % and over the population of 100000: 158 pieces / 42.9 %.
CONCLUSIONS: After the introduction of the new law for the economical use of
medications in 2006, the number of pharmacies significantly changed in Hungary.
However, this change in the number of pharmacies was inequal according to the
size of the population: in villages with a population lower than 2000 people there
was a decrease, while in cities with bigger population the number of pharmacies
significantly increased.
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OBJECTIVES: During 2009-2012 major health care reforms were proposed and im-
plemented in a number of nations, for example, Affordable Care Act in the United
States, AMNOG in Germany, HSPT in France, KVG in Switzerland, Ustawa Refun-
dacyjna in Poland and NHS proposed reform in the UK. These reforms have major
implications on pricing, market access and HEOR strategy for drug and device
products. METHODS: To understand the implications of these trends, we analyzed
2009-2012 reform bills and proposed changes worldwide. Additionally, we inter-
viewed public and private payers, key opinion leaders and payer-influencers to
understand implications of these reforms on drug and device manufacturers.
Stakeholders ranked various data collection methods on a scale of 1-10 (1-least
important and 10-most important). RESULTS: The global health care landscape is
expected to undergo significant change during 2012-2016. In the United States,
government will play increased role as a single payer, especially with?Medicare,
Medicaid and CHIP programs? which will cover 114 million Americans, at a cost of
$784 billion. In Germany, AMNOG bill marked the end of free drug pricing and
would lead to increased insurance premiums (now 15.5% of wages). In the UK, NHS
has proposed to replace PCTs with 500-1000 GP-led consortia and use value-based
pricing for expensive drugs and devices. Randomized controlled trial, budget im-
pact model and systematic reviews —ranked highest (7.5-9.1) among payers. Over-
all, payers view that in the future, health economic assessments would play critical
role in pricing, coverage and reimbursement of branded products. CONCLUSIONS:
This analysis shows that global health care landscape is expected to undergo sig-
nificant change during 2012-2016. Discussions with payers, KOLs and payer-influ-
encers highlights increased importance of HEOR data in the future.
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OBJECTIVES: To review the impact orphan drug (OD) legislation has had on inno-
vation and pricing of therapeutic products for rare diseases in the US, EU, and
Japan. METHODS: A systematic literature review was conducted, seeking English-
language studies published after the enactment of initial OD legislation in 1983.
EMBASE, Medline, and Business Source Complete were searched and results
screened for studies specifically assessing the impact of industry-focused policy
interventions using 1) measurable innovation- and pricing-related outcomes, and
2) specifying appropriate comparators. In addition to being abstracted for informa-
tion on research setting, counterfactuals, outcomes, and findings, the methodolog-
ical quality of included studies was evaluated with an adapted tool. RESULTS:
Twenty unique studies met the inclusion criteria: 14 discussing innovation out-
comes and 7 discussing pricing outcomes. Increasingly strong study designs have
been used to validate that that OD legislation has increased cross-market approv-
als and suggest the increasing role of small biotechnology companies. Select re-
search also shows a positive relationship between disease prevalence and the
likelihood of indicated ODs and is bolstered by well-controlled regression-continu-
ity studies showing sustained innovation in higher prevalence OD markets. How-
ever, some concerns are raised regarding innovation in low prevalence conditions
and conditions just above OD thresholds. Pricing studies were almost exclusively
focused on the EU. A multiple-regression analysis demonstrated that merely hav-
ing an OD designation leads to a higher price, with 4 weaker studies suggesting an
inverse relationship between rare disease prevalence and acquisition price.
CONCLUSIONS: Despite an abundance of opinion and case study pieces in OD
literature, specific studies of high internal validity exist, as do defined and usable
comparator group classifications. The reviewed studies ought to serve as valuable
information for policymakers considering policy extensions for ultra-orphans, in-
ternational markets, or other niche therapeutic areas, as well as demonstration of
best-practices in designing well-controlled studies evaluating biopharmaceutical
policies.
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The Japanese generic drug market is not well developed. The generic volume share
is 20% of the total market vs. 74% and 64% in the USA and UK. The slow uptake of
generics is often explained by the “Brand Lover” profile of Japan. No formal review
of drug policy has been undertaken to understand the slow uptake of generics.
OBJECTIVES: To review the current Japanese drug policy regarding generic drugs
and to appreciate the incentive and disincentive to use generic. METHODS: We
reviewed the current Japanese generic drug policy enacted by the Ministry of
Health, Labour and Welfare (MHLW), and the Japanese Generic Medicines Associ-
ation’s website. RESULTS: Major policies to enhance generic uptake were issued in
2002, 2006 and 2010. They required that prescriptions specify if substitution gener-
ics are acceptable, and provide some modest financial incentives for pharmacies
and hospitals to substitute only with the patient’s agreement. In 2012, INN pre-
scription is encouraged but not requested. The recent introduction of Japanese DRG
hospital funding, and the 2011 Japan-India Economic Partnership Agreement,
which opened the Japanese market to Indian generic drug manufacturers, are ex-
pected to boost the generic market. However, small pricing gaps between generic
and branded drugs, the lack of mandatory substitution and INN prescription, little
price discounting and little education towards the public might explain the slow
uptake of generics in Japan, relative to the West. CONCLUSIONS: Although the
“Brand Lover” assumption is candidly used to explain the lack of traction by generic
drugs, this review finds the lack of policy incentives to boost generic adoption,
better explain current levels of generics penetration. Shall the authorities be will-
ing to encourage generic uptake more effective policy incentive are needed.
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OBJECTIVES: Cost effectiveness analyses play a critical role in determining cover-
age of novel drugs and devices. Increasingly, payers are demanding subgroup anal-
yses to determine indications which would be covered by the national health sys-
tem or insurance agency. METHODS: To understand and review trends in use of
subgroup cost effectiveness analysis, we analyzed NICE HTAs for products ap-
proved in 2011-2012. Manufacturer submissions for CEA were compared to final
review and decision by HTA agency. Analogs were identified and case studies were
developed to further understand the use of subgroup analyses and cost effective-
ness models. RESULTS: Decisions made by NICE in 2011-2012 show increasing
trends towards the use of subgroup analysis for determining indications for cov-
erage by national payer bodies. During 2011-2012, 80% of the assessments included
subgroup analyses. Approximately half of them included cost effectiveness anal-
yses for various subgroups. Interestingly, the ICER values estimated by NICE for the
same subgroups showed a large variation (1X-3X fold difference) compared to ICER
values estimated by manufacturers. Selected case studies highlighted that for sev-
eral products NICE is recommending treatments only for subgroups whose ICER
values are within the cost effectiveness threshold. CONCLUSIONS: New products
need robust broader population and subgroup analyses for insurance coverage.
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OBJECTIVES: In 2006 a law for the economical use of medications was introduced
into the Hungarian legislation. This law – among others – facilitated the foundation
of new pharmacies. The aim of our study is to analyse the effect of that legislation
on the catchment population of community pharmacies. METHODS: Data were
derived from the pharmaceutical database of the Hungarian Health Insurance
Fund Administration (OEP), the only health care financing agency in Hungary. We
analysed the 5 years period between 2006-2010. The main indicator of our analyses
is the average population of one pharmacy (catchment population) in the counties
of Hungary. RESULTS: The average catchment population of a pharmacy was 4933
inhabitants (( 592, standard deviation, SD) in 2006, while in 2010 it decreased to
3.888 ( 450) inhabitants per pharmacy. We found the largest catchment popula-
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tion in 2006 in the following counties: Vas (6.326 inhabitants/pharmacy), Pest (5.913
inhabitants/pharmacy) and Nógrád (5.855 inhabitants/pharmacy), while the small-
est: Bács-Kiskun (4.034 inhabitants/pharmacy), Békés (4.165 inhabitants/phar-
macy) and Somogy (4.218 inhabitants/pharmacy). In 2010 Nógrád (5.123 inhabit-
ants/pharmacy), Vas (4.632 inhabitants/pharmacy) and Pest (4.424 inhabitants/
pharmacy) counties had the largest catchment population, while Bács-Kiskun
(3.222 inhabitants/pharmacy), Békés (3.458 inhabitants/pharmacy) and Csongrád
(3.441 inhabitants/pharmacy) had the lowest. CONCLUSIONS: Between 2007-2010,
as the consequence of the increasing number of pharmacies, the average catch-
ment population of pharmacies decreased significantly. The regional differences
among counties did not change during the study period and remained high.
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OBJECTIVES: The value of a drug can be expressed as cost needed to increase a unit
of health. However, summarizing the economic value of a molecule with multiple
indications is a complex process. The COVET study was conducted to facilitate a
comprehensive economic evaluation of adalimumab across all approved
indications. METHODS: An algorithm was developed to estimate the total eco-
nomic value of adalimumab. This value was calculated as the sum of the incre-
mental cost-utility ratios for treating rheumatoid arthritis, psoriatic arthritis, an-
kylosing spondylitis, Crohn’s disease, and psoriasis from a Italian National Health
Care (NHC) perspective. Estimates of the cost per quality-adjusted life year (QALY)
gained by using adalimumab instead of standard therapy were derived from pre-
viously developed economic models. The sum was weighted by the prevalence of
each of the diseases considered. Through a systematic literature review, the cost
per QALY gained by using other anti-TNF drugs was extrapolated. Subsequently, a
Boston matrix was developed to establish the relationship between demand and
health supply. A one-way sensitivity analysis (SA) performed to assess the robust-
ness of the results. RESULTS: The total economic value of adalimumab in Italy
amounted to €34,750 per QALY. The sensitivity analysis showed a cost per QALY
gained ranging between €27,447 and €40,412. The analysis of the Boston matrix
indicated that, with the exception of psoriasis, the cost per QALY gained by using
adalimumab instead of standard therapy was below the common WTP threshold.
In comparison with innovative molecules, the total economic value of adalimumab
was positive and sustainable. CONCLUSIONS: This study provides an estimate of
the cost-effectiveness of adalimumab across all approved indications that is below
the threshold value for health care interventions. The results should encourage
decision makers to facilitate patient access to this cost-effective treatment. They
may also promote research to develop innovative molecules that are even more
cost-effective.
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OBJECTIVES: As treatments trend towards personalized medicine for conditions
with certain genetic expressions, new opportunities exist for diagnostic tests to
change the standard of care and demonstrate positive economic impact to payers.
A systematic review of the role of economic evaluation to the coverage and pay-
ment of novel diagnostics has not yet been performed. The authors undertook this
analysis to examine what evidence exists to document the use of health economic
rationale and modeling to impact reimbursement and market access outcomes for
diagnostics. METHODS: A systematic review of published literature related to the
reimbursement and health technology assessment of diagnostics was conducted.
In addition, published coverage policies and HTAs in the US, UK, and Germany
related to personalized medicine diagnostics commercialized within the last de-
cade were reviewed. Policies and HTAs were graded to document the level of im-
pact economics played to decision-outcomes, if reported. Where specific refer-
ences were not made, a review of the citations referenced was conducted to see if
economic papers or models were included within their decision-framework.
RESULTS: Most published personalized medicine diagnostic coverage policies and
HTAs reference both clinical and economic evidence, though clinical data is prior-
itized. Of the policies analyzed, national HTA groups that reviewed novel diagnos-
tics or products with companion diagnostics, were most explicit in their consider-
ation of clinical and economic data. US payers were less likely to explicitly
reference economic data. CONCLUSIONS: As treatments are becoming more and
more dependent on companion diagnostic tests to influence treatment of disease
in a variety of subgroups, the processes by which diagnostics are approved, cov-
ered, and reimbursed will become more scrutinized. More standardized and trans-
parent incorporation of economic rationale and modeling into payer coverage,
payment, and HTA evaluation processes would clarify expectations and help com-
panies plan for HEOR activities.
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OBJECTIVES: With the formation of Clinical Commissioning Groups (CCGs) GP
Practices will come together to commission services for their local populations.
However, freedoms to be delegated from the Clinical Commissioning board may
mean that considerable ‘command and control’ will still be exerted from the cen-
tre. Secondary and primary research was undertaken to gain insight into how
devolved locality based commissioning is likely to impact on access to medicines.
METHODS: We reviewed 35 first wave CCGs in terms of population coverage, fi-
nancial stability and current Primary care Trust (PCT) activities in relation to Prac-
tice based commissioning. We then interviewed 5 NHS Experts to assess whether
these CCGs would be allowed the aspirational freedoms referred to in the 2012
Health and Social Care Act- in particular prescribing freedoms formerly under the
guidance of PCTs. Various information sources were used Care Quality Commis-
sion, Audit Commission, and Health Select Committee reports to support the in-
terpretation of the findings. RESULTS: The selected CCGs represented an homoge-
neous group of practices in that they had previously demonstrated financial
stewardship and collaborative working with their ‘host’ PCTs. Many CCGs had been
devolved the Commissioning budget by their PCTs and were routinely involved in
setting up medicines management protocols with their provider hospitals. Almost
half of the CCGs had coterminous medicines management contracts shared with
their PCTs. NHS experts raised issues around corporate and clinical governance
and how practices would fundamentally want to take on the devolved financial
responsibilities.CONCLUSIONS:The NHS reforms mean that £60 Billion of the total
health care budget will be under the control of CCGs. PCTs and Strategic Health
Authorities will be abolished and with a watered down role for NICE postcode
variation may be rife; access to medicines will continue to be fraught with many
layers of decision making and further delays.
PHP22
PHARMACOVIGILANCE IN QATAR – A PHARMACIST SURVEY
Wilbur K
Qatar University, Doha, Qatar
OBJECTIVES: Active domestic pharmacovigilance programs are necessary as ad-
verse drug reaction (ADR) data from other countries may overlook safety patterns
in local populations. The success of any surveillance system relies upon active
participation of reporters. The objective of this study was to describe pharmacist
reporting of suspected ADRs in Qatar to inform policy recommendations to the
Supreme Council of Health. METHODS: A 27-item survey was developed following
comprehensive literature review of relevant published research. Questions encom-
passed broad domains including: pharmacist knowledge of and experiences in
reporting suspected ADRs; attitudes towards health professional pharmacovigi-
lance roles; perceived barriers and facilitators to reporting; and recommendations
for improvements in this process. The web-based survey was formatted for elec-
tronic delivery and response for self-administration in English or Arabic by a con-
venience sample of over 500 Qatar pharmacists. RESULTS: The survey remained
open for two months between April 30 and June 30, 2011. Of the 142 (25%) total
responses, 116 (81.6%) surveys were completed beyond demographic data and in-
cluded information about prior suspected ADR reporting experiences. Knowledge
of ADR terminology and reporting purpose among the 116 (20%) responding phar-
macists was high, but only 34 (30%) had ever made a suspected ADR report in Qatar.
Most respondents expressed positive attitudes towards pharmacist roles in phar-
macovigilance activities, but inability to recognize a potential ADR or subsequently
access a reporting form were perceived barriers, with enhanced training and effi-
ciency in report submission corresponding identified facilitators to future partici-
pation. Hospital pharmacists were 7 times more likely than ambulatory-care based
pharmacists to have reported a suspected ADR in Qatar. CONCLUSIONS: Pharma-
cists in Qatar are willing to engage in pharmacovigilance activities if supported by
increased training and transparency in the reporting process. A national infra-
structure with capacity to collect and manage suspected ADR reports and promote
patient and medication safety is exigent.
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OBJECTIVES: In January 2011, the act for restructuring the pharmaceutical market
(“AMNOG”) was introduced in Germany. We analyzed the effects one year after
AMNOG’s implementation in an empirical study. The research focused on survey-
ing affected stakeholders, systematically summarizing their experiences, and
identifying topics of controversy. METHODS: Stakeholders were defined based on
statements during the AMNOG legislation: Payors, Pharmaceutical Industry, Na-
tional Regulatory Bodies, Scientific Experts, Patients, Care Providers, Politicians,
Pharmacies and External Service Providers. The benefit assessement process was
structured into 6 topics: Market Launch, Early Benefit Assessment, Price Negotia-
tions, Arbitration Procedure, Cost-Benefit Analysis and Process. 45 experts partic-
ipated in the structured survey (26% response rate), which consisted of closed
questions supplemented by optional open-ended questions (total 47 items). De-
scriptive statistical and dissimilarity analyses were performed. RESULTS: Between
the 9 stakeholder groups, several items were highly controversial: negotiation po-
sition of statutory health insurances (“GKV-Spitzenverband”) in rebate level nego-
tiations (distance index L21.17), use of European price reference in the arbitration
process (L21.08) and several others such as transparency of the benefit assess-
ment process (L20.95). Different response profiles were observed between stake-
holders but they yielded relatively low dissimilarities on cost-benefit assessment.
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